Company profile
OCULAR THERAPEUTIX, INC
NASDAQ:OCULBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Dexamethasone | approved | — | 102 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04945824 | — | terminated | 2021-06-01 | 2022-11-01 | Ocular Therapeutix, Inc. | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects |
| NCT04539548 | phase3 | completed | 2020-09-04 | 2023-12-21 | Ocular Therapeutix, Inc. | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract |
| NCT04050865 | phase3 | completed | 2019-08-05 | 2020-02-28 | Ocular Therapeutix, Inc. | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis |
| NCT05335122 | phase2 | completed | 2022-03-16 | 2024-01-24 | Ocular Therapeutix, Inc. | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) |
| NCT07235085 | phase3 | recruiting | 2025-11-17 | 2027-03-01 | Ocular Therapeutix, Inc. | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 208742 | NDA | OCULAR THERAPEUTIX INC | ||||
Loading… | ||||||